Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18989435 | 0.87 | RXRA (0.40) | CAPN1BACE1 | |
| SCHEMBL6244228 | 0.84 | SLC1A1 (0.50) | CAPN1CTSB | |
| SCHEMBL25382819 | 0.83 | CAPN1 (0.47) | CAPN1CTSBACE | |
| SCHEMBL3989376 | 0.83 | CAPN1 (0.47) | CAPN1CTSBACE | |
| SCHEMBL18989366 | 0.80 | TACR1 (0.42) | CAPN1 | |
| SCHEMBL3216189 | 0.78 | CTSK (0.51) | CTSBACEBACE1 | |
| SCHEMBL3221648 | 0.78 | CTSK (0.51) | CTSBACEBACE1 | |
| SCHEMBL5859417 | 0.78 | CTSB (0.54) | CTSB | |
| SCHEMBL5929919 | 0.78 | CTSB (0.54) | CTSB | |
| SCHEMBL2369340 | 0.77 | CAPN1 (0.61) | CAPN1CTSBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906104-B2 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092747-A1 | Aminediols for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | CAPN1 1974/4885CTSB 325/4885ACE 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.